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Introduction: The expression, mechanisms of regulation, and func-
tional impact of activin (INHBA) in esophageal adenocarcinoma
(EAC) have not been fully defined.
Methods: INHBA expression was examined in 46 esophageal sam-
ples (nine Barrett’s metaplasia (BM); seven BM/low-grade dyspla-
sia; eight low-grade dysplasia; seven high-grade dysplasia; 15 EAC)
using oligonucleotide microarrays and real-time reverse transcrip-
tion-polymerase chain reaction (RT-PCR) and in 90 tissue samples
(79 EAC; 8 dysplastic; 3 BM) using immunohistochemistry (IHC).
The proliferation of EAC cell lines FLO and OE-33 was examined
after treatment with exogenous activin. The proliferation of OE-33
was also examined after treatment with the activin inhibitor follista-
tin and INHBA-targeting siRNA. OE-33 and FLO cells were treated
with 5-aza-2deoxycytidine (5-AZA) and trichostatin A to investi-
gate the role of epigenetic regulation in INHBA expression.
Results: Primary EACs expressed 5.7-times more INHBA mRNA
than BM samples on oligonucleotide microarray. Transcript over-
expression in EAC relative to BM was confirmed on real-time
RT-PCR. IHC suggested higher INHBA protein expression in EAC
(69.6%) than in the dysplastic (37.5%) and BM samples (33.3%).
FLO and OE-33 treated with activin demonstrated increased prolif-
eration, and OE-33 cells treated with follistatin and INHBA-targeting
siRNA demonstrated reduced proliferation, relative to untreated
controls. Treatment of FLO cells with trichostatin A and 5-AZA
up-regulated INHBA mRNA and protein production by real time
RT-PCR and IHC.
Conclusions: INHBA is overexpressed in EAC relative to dysplastic
and BM tissue. INHBA overexpression may promote cell prolifera-
tion and may be affected by promoter demethylation and histone
acetylation in EAC cell lines.
Key Words: Esophageal adenocarcinoma, INHBA, Activin, Epige-
netic regulation.
(J Thorac Oncol. 2009;4: 455–462)
The incidence of esophageal adenocarcinoma (EAC) hasrisen dramatically over the past 30 years, however, the
overall 5-year survival has remained low at approximately
20%.1 Research dedicated toward the identification of novel
biomarkers will be useful in the early identification and
treatment of this lethal disease. Recently, gene expression
profiling has allowed researchers to correlate tumor expres-
sion patterns with clinical outcomes.2–4 Such high-throughput
technology has led to a better understanding of the molecular
pathways involved in neoplastic progression, and will be of
paramount importance in the fight against EAC.
Activin, the disulfide-linked homodimer of inhibin A
(INHBA), is a ligand in the transforming growth factor-beta
(TGF-) superfamily.5,6 The inhibin A can also bind the B
and  isoforms to form activin AB and inhibin, respectively.
Activin and inhibin are known to act in the hypothalamic-
pituitary-gonadal axis and have been implicated in multiple
biologic processes, including neoplastic progression.7–13
Chronic exposure to activin has been shown to promote
tumorigenicity, growth, invasion, and resistance to apoptosis
in esophageal squamous cell carcinoma.11 In addition, activin
overexpression in esophageal squamous cell carcinomas has
been associated with advanced stage and worse prognosis.12
Inhibin –knock-out mice express high levels of activin and
are prone to develop gonadal stromal tumors, supporting
activin’s role in tumorigenesis.13 Furthermore, colon, pros-
tate, pancreatic, and ovarian cancers have been reported to
overexpress activin,14–17 and women with endometrial or
cervical cancer have increased serum activin concentra-
tions.18 However, the diverse biologic function of activin is
demonstrated by its growth inhibitory effect on prostate
cancer cells, vascular endothelial cells, mammary epithelial
cells, plasmacytomas, and hepatocytes.19–24 In addition, ac-
tivin induces endodermal differentiation in human embryonic
stem cells.25
The role of INHBA and activin in EAC has not been
fully defined. In the current study, we demonstrate that
INHBA is overexpressed in EAC relative to both dysplastic
and Barrett’s metaplasia (BM) tissue. Our data also suggest
that EAC cell proliferation may be partially dependent on the
presence of activin. Finally, we demonstrate that expression
of INHBA in EAC cells is affected by a combination of
promoter demethylation and histone acetylation.
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PATIENTS AND METHODS
Patients and Tissues
Forty-six esophageal tissue samples were obtained
from consented patients who underwent esophagectomy for
adenocarcinoma at the University of Michigan Medical Cen-
ter (Ann Arbor, MI). Approval for this study was obtained
from the local Institutional Review Board. Tissues were
transported on ice in Dulbecco modified Eagle medium
(DMEM; Life Technologies, Inc., Carlsbad, CA), frozen in
liquid nitrogen, and stored at 80°C. Esophageal tissues
demonstrating at least 70% cellularity were identified on
hematoxylin and eosin-stained frozen sections. Two pathol-
ogists (T.J.G. and J.K.G.) classified the tissues as BM, BM/
low-grade dysplasia (LGD), LGD, high-grade dysplasia
(HGD), or EAC. Macrodissection was used to obtain samples
2 to 3 mm3 in size for mRNA and protein isolation. No
patients received neoadjuvant chemotherapy or radiotherapy.
Cell Lines
The cell lines used in this study, FLO and OE-33, were
derived from EAC, and have been previously described.26
Both cell lines were grown in DMEM (Invitrogen Corp.,
Carlsbad, CA) with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin/fungizone (Life Technologies,
Inc.) at 37°C in 5% CO2. Cells were treated when at 70%
confluence.
Oligonucleotide Microarray
The RNA was isolated, cRNA synthesized, and oligo-
nucleotide microarrays analyzed as previously described.27
Results from this data set have been previously published.28
Immunohistochemistry of Tissue Microarray
(TMA)
Immunohistochemical staining was performed on the
DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO
LSAB and diaminobenzadine as the chromogen, as previ-
ously described.27 De-paraffinized sections of the tissue mi-
croarray at 5- thickness were labeled with inhibin A
antibody (R&D Systems, Cat # MAB3381, Minneapolis,
MN, mouse, 1:20) after microwave antigen retrieval in 10
mM sodium citrate buffer, pH 6. Negative (no primary
antibody) and positive (placenta) controls were stained with
each immunohistochemical assay. The intensity and extent of
immunoreactivity was scored using a three-tier (negative (),
moderate (1), intense (2)) grading scheme. All tissue
microarrays were viewed with an Olympus BX40 microscope
(Olympus, Center Valley PA). Images were acquired using a
Spot Insight model 3.2.0 camera (Diagnostic Instruments,
Inc., Sterling Heights, MI) and Spot version 4.0.9 (Diagnostic
Instruments, Inc.) software.
Immunohistochemistry of Cells Lines
After plating on poly-L-lysine-coated glass slides, cells
were air-dried and fixed in 20°C acetone for 10 minutes.
Endogenous peroxidases were inactivated using 0.5% hydro-
gen peroxide. Cells were stained with the Vectastain ABC Kit
(Vector Laboratories, Burlingame, CA, Cat # PK-6102,
mouse IgG) and Peroxidase Substrate Kit (Vector, Cat #
SK-4100) according to the manufacturer’s instructions. In-
hibin A antibody (R&D Systems, Cat # MAB3381, 1:20)
was used as the primary antibody. Negative controls (no
primary antibody) were stained with each slide.
Western Blot Analysis
Western blot analysis was performed as previously
described with slight variations.26 Briefly, 15 l of FBS or
calf serum (CS) was loaded onto a 10% sodium dodecyl
sulfate polyacrylamide gel and electrophoresed. Inhibin A
antibody (R&D Systems, Cat # MAB3381, 2 g/ml) and a
secondary antibody (GE Healthcare UK Limited, Chalfont St.
Giles, UK, Cat # NA931V, goat antimouse, 1:10,000) were
used for protein detection.
Real-Time Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted with the RNeasy Mini Kit
(Qiagen, Valencia, CA, Cat # 74104) and cDNA was made
using the Superscript II Kit (Invitrogen, Cat # 18064). Real-
time reverse transcription-polymerase chain reaction (RT-
PCR) was performed on the Rotor-Gene 6000 (Corbett Life
Science, Sydney, Australia) with the Platinum SYBR Green
Kit (Invitrogen, Cat # 11733-038). The INHBA oligo primers
(Invitrogen) for real-time RT-PCR included forward
INHBArt2f (5-AAG TCG GGG AGA ACG GGT ATG
TGG-3) and reverse INHBArt2r (5-TCT TCC TGG CTG
TTC CTG ACT CG-3). Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) expression was used to standardize the
INHBA results using GAPDH primers (Invitrogen). Optimal
annealing temperatures were determined, and melt curves
were analyzed to ensure RT-PCR results.
WST-1 Cell Proliferation Assays
Cell viability and proliferation were assessed using Cell
Proliferation Reagent WST-1 (Roche Applied Science, Indi-
anapolis, IN, Cat # 11644807001). The experiments were
performed in 96-well plates at two different cell densities
(FLO: 6.0  103 and 8.0  103 cells/well; OE-33: 1.5  103
and 2.5  103 cells/well). Absorbance was measured on a
Biotek EL-312e microplate reader (Biotek Instruments, Wi-
nooski, VT) at 96 hours.
Treatment of Cell Lines with Activin and
Follistatin
Twenty-four hours after plating, FLO and OE-33 cells
were treated with 1, 10, and 100 ng/ml activin (Peprotech,
Inc., Cat # 120-14, Rocky Hill, NJ) in DMEM with 10% FBS
or 10% CS. In addition, OE-33 cells were treated with 1, 10,
and 100 ng/ml follistatin (Peprotech, Inc., Cat # 120-13) in
DMEM with 10% FBS. All activin and follistatin treatment
experiments were performed in quadruplicate.
Transfection of OE-33 Cells with
INHBA-Targeting Small-Interfering RNA
(siRNA)
Transient transfection of OE-33 cells with INHBA-
targeting siRNA was performed as previously described.28
Briefly, OE-33 cells were plated at a density of 2.0  103
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cells/well in DMEM with 10% FBS in a 96-well format for
determination of the optimal siRNA transfection conditions.
Twenty-four hours after plating, cells were treated with
INHBA-targeting SMART pool siRNA (Dharmacon, Lafay-
ette, CO) in the presence of 0.1 l Lipofectamine RNAiMAX
(Invitrogen) in 9.9 l Opti-MEM I (Invitrogen). INHBA
knockdown efficiency was assessed by real-time RT-PCR.
An optimal working concentration of 10 nM siRNA was
used to perform cell proliferation assays. Forty-eight hours
after initial transfection, half of the plates were retrans-
fected with 10 nM INHBA-targeting siRNA. Transfected
cells were incubated for a total of 96 hours at 37°C before
gene silencing analysis. Cells treated with transfection
reagent were used as a control. All siRNA experiments
were performed in quadruplicate.
Treatment of FLO and OE-33 Cells with
Trichostatin A (TSA) and 5-aza-2
Deoxycytidine (5-AZA)
FLO and OE-33 cells were serum starved for 24 hours
before treatment to synchronize their cell cycles. Cell lines
were then treated with trichostatin A (TSA) at a concentration
of 300 nM and/or 5-aza-2 deoxycytidine (5-AZA) at a
concentration of 5 M in DMEM with 10% FBS. Cells
receiving combination treatment were simultaneously ex-
posed to 300 nM TSA and 5 M 5-AZA. The TSA and
5-AZA was dissolved in dimethyl sulfoxide (DMSO; Sigma
Aldrich, Cat # D4540, St Louis, MO) and control cells were
treated with equivalent amounts of DMSO. Cells treated with
TSA were harvested at 12 or 24 hours and those treated with
5-AZA were harvested at 48, 72, or 96 hours. Combination
plates were treated with 5-AZA for 48, 72, or 96 hours and
TSA for 24 hours. Cell pellets for mRNA analysis were
frozen in liquid nitrogen and stored at 80°C until mRNA
was extracted for real-time RT-PCR. All TSA and 5-AZA
experiments were performed in duplicate. Cells for immuno-
histochemistry (IHC) analysis were immediately suspended
in PBS and plated on poly-L-lysine coated slides using a
Shandon Cytospin 3 machine (Thermo Fisher Scientific,
Waltham, MA).
Correlation between INHBA and Histone
Deacetylase, Histone Acetyltransferase, and
DNA Methyltransferase Expression
To further examine the potential role of histone acety-
lation and promoter methylation in the regulation of INHBA
expression, we examined the oligonucleotide microarray ex-
pression of histone deacetylases (HDAC), histone acetyl-
transferases (HAT), and DNA methyltransferases (DNMT) in
the 15 EAC samples. The HDAC, HAT, and DNMT expres-
sion values were then correlated with INHBA expression.
Statistical Analysis
The Fisher’s exact test was used to compare IHC
staining between BM, dysplastic, and EAC samples. The t
test was used to assess the significance of changes in prolif-
eration after treatment. Spearman analysis was used to cor-
relate INHBA gene expression with that of the HDACs,
HATs, and DNMTs. A p value 0.05 was deemed signifi-
cant. All statistical analyses were performed using R version
2.7.0 (Vienna, Austria).
RESULTS
INHBA mRNA is Overexpressed in EAC
Oligonucleotide microarrays were used to measure the
level of INHBA expression in 46 esophageal tissue samples (9
BM; 7 BM/LGD; 8 LGD; 7 HGD; 15 EAC). The EAC
expressed two-fold more INHBA mRNA than the mean of the
BM in 11 of 15 (73.3%) samples and at least four-fold more
expression in 9 of 15 (60%) samples (Figure 1). On average,
the EAC expressed 5.7-times more INHBA mRNA than the
BM tissues. The HGD tissue samples demonstrated two-fold
expression relative to BM in 2 of 7 (28%) cases. Real-time
RT-PCR was used to confirm that INHBA was overexpressed
in the 15 EAC samples relative to BM (Figure 2). One LGD
tissue sample examined in the oligonucleotide microarray
was unavailable; therefore, real-time RT-PCR was performed
on 45 esophageal tissue samples.
Inhibin A Protein Overexpression Suggested
on Esophageal Tissue Microarray
Immunohistochemical staining of a TMA containing
BM, dysplastic tissue, and EAC suggested greater inhibin A
FIGURE 1. Oligonucleotide microarray
analysis of 46 esophageal specimens dem-
onstrated at least two-fold expression in 11
of 15 (73.3%) and four-fold expression in 9
of 15 (60%) of esophageal adenocarcinoma
(EAC) relative to Barrett’s metaplasia (BM).
x axis represents tumor identifier; y axis rep-
resents transcript expression relative to BM.
BM, Barrett’s metaplasia; LGD, low-grade
dyslasia; HGD, high-grade dyslasia; EAC,
esophageal adenocarcinoma.
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expression in EAC than BM and dysplastic samples. All
inhibin A staining was cytoplasmic. Although not statisti-
cally significant, immunoreactivity was found in 69.6% (55
of 79) of EAC (Figures 3C, D), although only 37.5% (3 of 8;
p 0.11) of dysplastic samples and 33.3% (1 of 3; p  0.23)
of BM (Figures 3A, B) demonstrated INHBA immunore-
activity.
Activin Induces Proliferation in FLO and OE-33
Cells
EAC cell lines FLO and OE-33 treated with activin at
concentrations ranging from 1 to 100 ng/ml demonstrated
increased proliferation relative to untreated controls at 96
hours. The effect of activin treatment was greater in the
presence of CS than FBS in both cell lines. FLO cells
demonstrated the greatest growth proliferative response after
treatment with 100 ng/ml activin in CS (159%) and with 10
ng/ml activin in FBS (154%) (Figure 4A). Treatment with
100 ng/ml activin induced the greatest OE-33 growth prolif-
erative response in both CS and FBS, at 126 and 123% of
controls, respectively (Figure 4B). The growth proliferative
response was inversely related to the baseline INHBA tran-
script expression as assessed by real time RT-PCR. FLO cells
demonstrated low INHBA transcript levels (Ct  27.2,
GAPDH Ct  11.6), although OE-33 cells had moderate
INHBA transcript expression (Ct 24.5, GAPDH Ct 11.8).
At baseline, neither FLO nor OE-33 cells demonstrated
inhibin A immunoreactivity on Western blot or IHC.
FIGURE 2. Real-time reverse transcription-poly-
merase chain reaction (RT-PCR) analysis of 45
esophageal specimens used in the oligonucleotide
microarray (Figure 1) confirming overexpression
of INHBA in esophageal adenocarcinoma (EAC)
relative to Barrett’s metaplasia (BM). x axis repre-
sents tumor identifier; y axis represents transcript
expression relative to BM. BM, Barrett’s metapla-
sia; LGD, low-grade dyslasia; HGD, high-grade
dyslasia; EAC, esophageal adenocarcinoma.
FIGURE 3. Representative sections of tissue microarray. A,
and (B) Inhibin A protein staining was not detected in most
Barrett’s metaplasia, but was seen in (C) and (D) 69.6% of
esophageal adenocarcinomas by immunohistochemistry. A,
and (D) 40 magnification; B, 20 magnification; C, 10
magnification.
FIGURE 4. A, FLO and (B) OE-33 cells treated with activin
demonstrated increased proliferation at 96 hours as assessed
using WST-1 assays. The effect of activin treatment was
greater in calf serum (CS) than in fetal bovine serum (FBS).
All experiments repeated in quadruplicate. *p  0.05.
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Inhibin A is More Abundant in Fetal Bovine
Serum than Calf Serum
We hypothesized that the blunted proliferative response
seen in the presence of FBS upon activin treatment was due
to a higher inhibin A concentration in FBS than CS. Inhibin
A protein was seen in all four replicate FBS lanes on
Western blot, but none of the four CS lanes, suggesting a
higher concentration of activin in FBS than CS (data not
shown). This finding was repeated and confirmed with dif-
ferent batches of FBS and CS.
Inhibin A Inhibitor Follistatin Reduces
Proliferation in OE-33 Cells
EAC cell line OE-33 treated with 1 to 100 ng/ml
follistatin demonstrated a dose-dependent reduction in pro-
liferation relative to untreated controls, with a maximum of
23% reduction in proliferation (Figure 5A).
Transfection of OE-33 Cells with INHBA-
Targeting siRNA Affects INHBA Expression and
Cell Proliferation
An INHBA-silencing efficiency of 70% relative to
mock-controls was achieved by transfecting OE-33 cells with
INHBA-targeting siRNA at a concentration of 10 nM (data
not shown), as assessed using real-time RT-PCR. This con-
centration of INHBA-targeting siRNA produced a 5% reduc-
tion in proliferation at 96 hours. When cells were retrans-
fected 48 hours after the initial transfection, a 10% reduction
in proliferation was observed at 96 hours (Figure 5B).
Epigenetically Mechanisms May Affect INHBA
Expression in EAC Cell Lines
We treated FLO and OE-33 cells with 5-AZA and TSA
to determine if epigenetic regulation affected INHBA expres-
sion. FLO, a cell line with low baseline INHBA expression,
demonstrated a 51.7-fold (range, 38.3–78.8-fold) increase in
mRNA production relative to the mean of the controls with
12 hours of TSA exposure (Figure 6A). When cells were
treated with a combination of TSA for 24 hours and 5-AZA
for 96 hours, a 46.1-fold (range, 20.5–60.5-fold) increase in
INHBA mRNA expression was observed. OE-33 cells, which
demonstrated higher baseline INHBA expression, exhibited
an attenuated INHBA up-regulation with TSA and 5-AZA
treatment (Figure 6B). Consistent with our real-time RT-PCR
results, IHC of FLO cells treated with TSA for 12 hours
demonstrated up-regulated inhibin A protein expression
(Figure 7B) relative to the untreated control (Figure 7A). This
protein up-regulation was not seen in the OE-33 cells treated
with TSA and 5-AZA (data not shown).
FIGURE 5. OE-33 cells treated with (A) activin inhibitor fol-
listatin and (B) 10 nM INHBA-targeting siRNA demonstrated
reduced proliferation at 96 hours relative to mock controls
using WST-1 assays. Repeat transfection after 48 hours re-
sulted in further growth-inhibition relative to controls. All
experiments repeated in quadruplicate.
FIGURE 6. INHBA mRNA production in (A) FLO was up-
regulated upon treatment with histone deacetylase inhibitor
trichostatin A (TSA) and demethylating agent 5-aza-2deoxy-
cytidine (5-AZA). B, A significantly blunted response was
seen upon exposure of OE-33 to TSA and 5-AZA.
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Correlation between INHBA and HAT1
Expression
We compared the oligonucleotide microarray expres-
sion of INHBA to the HDACs, HATs, and DNMTs in the 15
EAC samples using Spearman correlation analysis. No sig-
nificant correlations were found between INHBA and the
HDACs or DNMTs. However, HAT1 was found to have a
strong positive correlation (  0.442) with INHBA expres-
sion (see Appendix). This correlation is consistent with our
cell line findings. However, due to the small sample size, this
correlation failed to reach statistical significance (p 0.087).
DISCUSSION
We have demonstrated that INHBA mRNA and protein
are overexpressed in primary EAC relative to Barrett’s and
dysplastic tissue. In addition, we have shown that the addition
of exogenous activin leads to EAC cell proliferation. Further-
more, partial EAC activin-dependency is suggested by the
decrease in proliferation seen with follistatin and INHBA-
targeting siRNA treatment in OE-33.
Upon treatment with high concentrations of activin in
the presence of FBS, FLO cells demonstrated an attenuated
proliferative response. This effect was not seen when the cells
are treated in CS, which unlike FBS, contains no activin by
Western blot. These findings suggest that at high doses,
activin might have growth inhibitory effects on some EAC
cell lines. The complex actions of activin are characteristic of
the TGF- superfamily, which are known to exert both tumor
suppressive and oncogenic effects. In the current model,
tumor suppressor activities dominate in normal tissues, but
changes in cellular response may promote oncogenesis in
tumors.29–31 Activin seems to exert a similar dose-dependent
dual effect on FLO cells, which express small amounts of
activin at baseline. The moderate INHBA-expressing cell line,
OE-33, demonstrated a blunted proliferative response with
activin treatment. However, the growth-proliferative effects
of activin are seen in a dose-dependent manner, suggesting
that OE-33 cells tolerate higher concentrations of activin
without growth inhibition.
Although the exact concentrations of specific growth
factors are not available for most commercially obtained
serums, multiple studies have demonstrated that the concen-
tration of activin A rises in maternal serum throughout
pregnancy and is present at high levels in amniotic fluid and
fetal serum.32–38 In addition, studies have suggested that
deletion of INHBA in mice results in severe craniofacial
abnormalities, including cleft palate and lack of lower inci-
sors. Furthermore, lack of type IIA activin receptors in fetal
mice results in impaired reproductive function.39,40 Such
evidence implicates the role of activin A in fetal develop-
ment, and is consistent with our western blots demonstrating
detectable levels of the inhibin A in fetal bovine serum, but
not in CS.
Follistatin was first identified as an inhibitor of pituitary
FSH secretion41,42 and was subsequently found to serve as an
activin-binding compound.43 Follistatin is known to bind
activin with high affinity (50–500 pM), thereby regulating its
function.44 When we treated OE-33 cells with follistatin, a
moderate decrease in proliferation was seen, which was
consistent with activin inhibition. A slightly smaller, but
statistically significant, growth inhibitory effect was also seen
upon treatment of OE-33 with INHBA-targeting siRNA. Al-
though follistatin will bind other members of the TGF-
superfamily with very low affinity, and siRNA transfection
has the potential to exert off-target effects, our data consis-
tently demonstrated a reduction in cell proliferation with
differing methods of activin inhibition. The moderate growth
reduction seen in OE-33 cells with activin inhibition suggests
agents targeting INHBA may be therapeutically useful, po-
tentially in combination with other agents.
The growth-proliferative effects of activin in two EAC
cell lines prompted us to explore mechanisms for its overex-
pression. Previous reports have established that epigenetic
mechanisms can affect gene expression in normal and neo-
plastic tissues.45–47 Our cell line data and microarray corre-
lation analysis suggest that the overexpression seen in a
subset of primary tumors might be due to histone acetylation
and/or promoter demethylation. The greatest increase in IN-
HBA mRNA expression occurred in the low-INHBA express-
ing cell line, FLO, after 12 hours of TSA exposure. Treatment
of FLO with TSA beyond 12 hours, alone or in combination
with 5-AZA, led to a smaller increase in INHBA expression.
As TSA and 5-AZA are globally acting agents, prolonged
exposure may affect other genes that result in the down-
regulation of INHBA transcription. The blunted INHBA up-
regulation seen in OE-33 cells relative to FLO cells may be
a reflection of the higher baseline expression of OE-33, thus
resulting in a smaller fold-increase. Alternatively, OE-33 and
FLO may have differing mechanisms of regulating INHBA
expression.
FIGURE 7. Immunohistochemistry of A, un-
treated FLO cells did not demonstrate inhibin A
protein expression. B, Treatment of FLO cells for
12 hours with trichostatin A (TSA) significantly
up-regulated inhibin A protein expression (40
magnification).
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INHBA may represent a novel target in the treatment of
EAC. Clearly, INHBA overexpression is not the sole mechanism
responsible for the unregulated growth of EAC, as some EACs
do not express high levels of INHBA and inhibition of INHBA
does not completely arrest EAC growth. However, our data
show that activin exposure does stimulate proliferation and that
EAC cells are partially dependent on activin exposure. Thus, the
use of activin-antagonists, such as follistatin, monoclonal anti-
bodies, and small molecule inhibitors holds therapeutic poten-
tial, especially in combination with other agents. Since INHBA is
widely expressed and has a variety of physiologic functions, the
feasibility of systemic therapy needs further examination before
in vivo application. Our findings also suggest that that histone
acetylation and promoter demethylation may play a role in the
INHBA overexpression observed in a subset of EAC. This study
provides data to support the continued investigation of INHBA in
the progression of EAC.
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APPENDIX. Expression of INHBA and HAT1 in EAC
Probe ID Gene EAC1 EAC2 EAC3 EAC4 EAC5 EAC6 EAC7 EAC8 EAC9 EAC10 EAC11 EAC12 EAC13 EAC14 EAC15
210511_s_at INHBA 1.33 1.82 1.79 1.58 10.07 5.36 4.07 5.00 8.98 8.61 7.10 2.78 2.08 16.21 5.14
203138_at HAT1 0.65 0.69 1.12 0.69 0.97 1.01 0.77 1.03 0.87 0.60 0.99 1.09 1.77 2.07 0.78
EAC, esophageal adenocarcinoma.
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